Mouse Anti-IL2RB Recombinant Antibody (clone MIK-BETA 1) (CAT#: HPAB-0249CQ)

Figure 1 Hu-Mikβ1 inhibits IL-2– and IL-15–induced proliferation of 32Dβ cells that express human IL-2/IL-15Rβ and the murine common γ-c.

The dose-response effects of addition of Hu-Mikβ1 Ab were evaluated on IL-2 (1.0 ng/mL)– and IL-15 (20 ng/mL)–induced proliferation of 32Dβ cells. In these cells, which express only human IL-2/IL-15Rβ and the common γ-c, but not IL-2Rα or IL-15Rα, IL-2– and IL-15–induced proliferations were inhibited by the addition of Hu-Mikβ1.

Waldmann, T. A., Conlon, K. C., Stewart, D. M., Worthy, T. A., Janik, J. E., Fleisher, T. A.,... & Decker, J. R. (2013). Phase 1 trial of IL-15 trans presentation blockade using humanized Mik-Beta-1 mAb in patients with T-cell large granular lymphocytic leukemia. Blood, 121(3), 476-484.

Figure 2 FACS analyses of Hu-Mikβ1 saturation was performed on ex vivo CD8+ T cells after administration of 1.5 mg/kg of Hu-Mikβ1.

Waldmann, T. A., Conlon, K. C., Stewart, D. M., Worthy, T. A., Janik, J. E., Fleisher, T. A.,... & Decker, J. R. (2013). Phase 1 trial of IL-15 trans presentation blockade using humanized Mik-Beta-1 mAb in patients with T-cell large granular lymphocytic leukemia. Blood, 121(3), 476-484.

Figure 3 Pharmacokinetic analysis of Hu-Mikβ1 was performed after administration of 0.5, 1.0, and 1.5 mg/kg of Hu-Mikβ1 Ab to patients with T-LGL leukemia.

After administration of 0.5 (○), 1.0 (■), and 1.5 (▾) mg/kg of Hu-Mikβ1, the serum concentration of the Ab was quantitated at subsequent time points in patients with T-LGL leukemia. Hu-Mikβ1 was not demonstrable in the serum after the 2-week time point after 0.5 mg/kg administration, but was still present in the circulation at day 22 at concentrations of 160, 400, and 2530 pg/mL in the 3 patients receiving 1.5 mg/kg of Hu-Mikβ1.

Waldmann, T. A., Conlon, K. C., Stewart, D. M., Worthy, T. A., Janik, J. E., Fleisher, T. A.,... & Decker, J. R. (2013). Phase 1 trial of IL-15 trans presentation blockade using humanized Mik-Beta-1 mAb in patients with T-cell large granular lymphocytic leukemia. Blood, 121(3), 476-484.

Figure 4 PBMCs from patients with T-LGL leukemia do not manifest ex vivo spontaneous proliferation in a 6-day ex vivo culture.

PBMCs from patients with T-LGL leukemia were placed in a 6-day culture in1640 media containing 10% FCS and proliferation was assessed by the evaluation of the uptake of thymidine added during the last 4 hours of culture. There was no meaningful thymidine uptake, indicating that there was essentially no ex vivo proliferation of PBMCs from the 6 patients studied with monoclonal T-LGL leukemia. When 20 000 pg/mL of IL-15 was added to the T-LGL of 5 patients, there was an increase in the geometric mean proliferation from 472-5 565 cpm per 1 millicurie of 3H thymidine added. This proliferation was inhibited to baseline levels of 728 cpm on addition of 10 μg/mL of Hu-Mikβ1 at the onset of the cultures.

Waldmann, T. A., Conlon, K. C., Stewart, D. M., Worthy, T. A., Janik, J. E., Fleisher, T. A.,... & Decker, J. R. (2013). Phase 1 trial of IL-15 trans presentation blockade using humanized Mik-Beta-1 mAb in patients with T-cell large granular lymphocytic leukemia. Blood, 121(3), 476-484.